Why Corcept Therapeutics Plummeted by 50% Today
The final day of 2025 saw the company get a sharp “no” from a top regulator. No biotech wants to exit a year with a regulatory rejection. Unfortunately for Corcept Therapeutics (CORT 50.42%) and its shareholders, that’s exactly what happened to the California-based company. As a result, the company’s share price eroded by just over…